Global Growth Driving Factors:

Growth in Fertility Test Market is primarily driven by the increasing first-time pregnancy age in women, declining fertility rate among men and women, growing number of women suffering from disorders such as PCOS, emergence of advanced ovulation monitors, and the increased awareness of fertility testing in both developed as well as developing countries.

On the other hand, the unproven accuracy of urine-based ovulation monitors in women suffering from PCOS and the lesser precision to confirm ovulation using ovulation prediction kits are the factors that are expected to restrain market growth to a certain extent in the coming years.

Opportunity: Emerging nations to offer new growth avenues

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities to players operating in the fertility test market. The demand for fertility and ovulation monitors in emerging countries is expected to grow significantly in the coming years due to the rising infertility rates, increasing prevalence of PCOS and obesity, growing fertility education, and easy availability of fertility monitors through e-commerce websites, pharmacies, and retail shops/drugstores. In addition, friendly regulatory policies and less competition among players in developing markets (as compared to developed markets) have encouraged companies to focus on emerging countries.

Projected Revenue Growth:

The fertility test market is projected to reach USD 680 Million by 2025 from USD 472 Million in 2020, at a CAGR of 7.5 % the forecast period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139945432

Key Players:

Swiss Precision Diagnostics (Switzerland), Church & Dwight (US), Prestige Brands Holdings (US), bioZhena (US), Fairhaven Health (US), Fertility Focus (UK), Geratherm Medical (Germany), Hilin Life Products (US), UEBE Medical (Germany), AdvaCare Pharma (US), AVA (Switzerland), Babystart (UK), Valley Electronics (Germany), Sensiia (UK), and Mira Care (US), among others are some of the major players operating in the global fertility test market.

Growth Strategies Adopted By Them:

The competitive landscape includes the analysis of the key growth strategies adopted by major players between 2017–2020 to expand their global presence and increase their market shares in fertility test market. The key growth strategies adopted by the top players in the market include product launches and approvals, agreements, expansions, and acquisitions. Product launches and enhancement were the most widely adopted growth strategies by market players in the last three years to garner a larger share of the market.

As of 2020, Swiss Precision Diagnostics holds the leading position in the global fertility test market. The company is one of the leading manufacturers and suppliers of fertility/ovulation tests for women. Clearblue is the flagship product of the company and has a very strong brand presence in countries such as the US, the UK, and Europe. Along with this, the company’s wide distribution network and innovative marketing strategies are the key factors contributing to its dominant share in the market. With the aim to maintain its dominant share in this highly competitive market, SPD focuses on product launches as its key growth strategy.

Church & Dwight (US) held the second position in the global fertility test market. The company has a strong geographic presence with subsidiaries across seven countries, including the UK, France, Germany, Canada, Mexico, Australia, and Brazil. Church & Dwight provides its fertility testing products to a large customer base through its wide distribution network across 130 countries. The company is focusing its efforts to increase awareness about issues related to infertility and help women understand their reproductive health and fertile window to improve the conception rate. Church & Dwight is expected to witness growth in the coming years due to its multiple initiatives to create awareness regarding fertility.

Prestige Brands Holdings (US) is engaged in the manufacturing, marketing, and distribution of OTC healthcare and household cleaning products in the US, Canada, Australia, and other international markets. It sold its women’s healthcare, pregnancy, and fertility testing products under the brand e.p.t. As of January 2017, NFI Consumer Healthcare (US), a division of Gregory Pharmaceutical Holdings (US), acquired the e.p.t brand from Prestige Brands Holdings. NFI is an innovative consumer products company that manufactures and distributes several brands of nutritional supplements in the Health and Beauty Care Category.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=139945432

The home care settings segment is expected to register the highest CAGR during the forecast period

Based on end-users, the fertility test market has been segmented based on end-user category—home care settings, hospitals and fertility clinics, and other end users. The large share and high growth of this segment can be attributed to the inclination of patients toward self-monitoring of healthcare conditions, easy access to fertility and ovulation monitors on e-commerce websites, availability of user-friendly and easy-to-handle devices, and the growing preference for the confidentiality of test results.